<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8711562</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6325</journal-id>
<journal-id journal-id-type="nlm-ta">Oncogene</journal-id>
<journal-id journal-id-type="iso-abbrev">Oncogene</journal-id>
<journal-title-group>
<journal-title>Oncogene</journal-title>
</journal-title-group>
<issn pub-type="ppub">0950-9232</issn>
<issn pub-type="epub">1476-5594</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27841866</article-id>
<article-id pub-id-type="pmc">6609160</article-id>
<article-id pub-id-type="doi">10.1038/onc.2016.312</article-id>
<article-id pub-id-type="manuscript">NIHMS1035674</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neomorphic mutations create therapeutic challenges in cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Takiar</surname>
<given-names>Vinita</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ip</surname>
<given-names>Carman K.M.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gao</surname>
<given-names>Meng</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mills</surname>
<given-names>Gordon B.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cheung</surname>
<given-names>Lydia W.T.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Departments of Radiation Oncology and Cancer Biology, University of Cincinnati College of Medicine, UC Barrett Cancer Center, 234 Goodman Street Cincinnati, OH 45219, USA</aff>
<aff id="A2"><label>2</label>Department of Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Unit 1058, Houston, TX 77030, USA</aff>
<aff id="A3"><label>3</label>School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong S.A.R</aff>
<author-notes>
<corresp id="CR1"><bold>Correspondence</bold> Gordon B. Mills. <email>gmills@mdanderson.org</email>Lydia W.T. Cheung. <email>lydiacwt@hku.hk</email></corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P33">Conflict of interest</p>
<p id="P34">The authors declare no conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>1</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>14</day>
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<day>23</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>03</day>
<month>7</month>
<year>2019</year>
</pub-date>
<volume>36</volume>
<issue>12</issue>
<fpage>1607</fpage>
<lpage>1618</lpage>
<!--elocation-id from pubmed: 10.1038/onc.2016.312-->
<abstract id="ABS1">
<p id="P1">Oncogenesis is a pathologic process driven by genomic aberrations, including changes in nucleotide sequences. The majority of these mutational events fall into two broad categories: inactivation of tumor suppressor genes (hypomorph, antimorph or amorph) or activation of oncogenes (hypermorph). The recent surge in genome sequence data and functional genomics research has ushered in the discovery of aberrations in a third category: gain-of-novel-function mutation (neomorph). These neomorphic mutations, which can be found in both tumor suppressor genes and oncogenes, produce proteins with entirely different functions from their respective wild-type proteins and the other morphs. The unanticipated phenotypic outcomes elicited by neomorphic mutations imply that tumors with the neomorphic mutations may not respond to therapies designed to target the wild-type protein. Therefore, understanding the functional activities of each genomic aberration to be targeted is crucial to devising effective treatment strategies that will benefit specific cancer patients.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>